Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT00843882

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This randomized phase III trial studies lenalidomide to see how well it works with or without epoetin alfa in treating patients with myelodysplastic syndrome and anemia. Lenalidomide may stop the growth ofmyelodysplastic syndrome by blocking blood flow to the cells. Colony stimulating factors, such as epoetin alfa, may increase the number of immune cells found in bone marrow or peripheral blood. It is not yet known whether lenalidomide is more effective with or without epoetin alfa in treating patients withmyelodysplastic syndrome and anemia.

Status: 
Recruiting
Study Date: 
Fri, 01/01/2010 to Sat, 04/01/2017
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
iological: Epoetin Alfa Given SC Other Names: EPO Epogen Eprex Procrit Other: Laboratory Biomarker Analysis Correlative studies Drug: Lenalidomide Given PO Other Names: CC-5013 CC5013 CDC 501 Revlimid